Altman Clinical and Translational Research Institute Building Opens March 4

Stunning structure will house array of scientists and centers dedicated to speeding basic research into new treatments and therapies —

Rising above Interstate 5 on the east campus of University of California, San Diego, the Altman Clinical and Translational Research Institute Building (ACTRI), a five-sided polygon of glass, steel and grooved concrete, officially opens its doors March 4 in a ribbon-cutting ceremony.

“The building is an architectural marvel, but more important is what it represents and the work that will go on inside,” said UC San Diego Chancellor Pradeep K. Khosla. … Read the Full Story from the UC San Diego Newsroom


Dr. Gary Firestein

Dr. Gary Firestein

The director of the Clinical and Translational Research Institute at UC San Diego is Gary S. Firestein, MD, Professor of Medicine and Dean and Associate Vice Chancellor of Translational Medicine at UC San Diego.

CTRI opened in 2010 as a part of the national Clinical and Translational Science Award consortium through a five-year, $37.2 million grant from the National Center for Advancing Translational Science of the National Institutes of Health. CTRI received a $52 million renewal grant last year.

More about the activities of the CTRI

 

UC San Diego and GSK Collaborate to Eradicate Cancer Stem Cells, Treat Leukemia

First California institution selected to participate in GSK’s bench-to-bedside academia-industry collaboration program —

Researchers at the University of California, San Diego School of Medicine and Moores Cancer Center are working with GSK on a bench-to-bedside project to treat leukemia and other diseases by eliminating cancer stem cells. The collaboration is part of GSK’s Discovery Partnerships with Academia (DPAc) program, where academic partners become core members of drug-hunting teams. Catriona Jamieson, MD, PhD, associate professor of medicine and chief of the Division of Regenerative Medicine, will lead UC San Diego’s effort in the new DPAc team. … Read the full story from the UC San Diego Newsroom

Nation’s First Angioedema Treatment Center Is at UC San Diego

US Hereditary Angioedema Association and four corporate partners endow center to treat rare hereditary swelling disease —

It is rare for an “orphan” disease (typically a condition that affects fewer than 200,000 people nationwide) to have a specific center dedicated to providing treatment and research. And it is even more unusual for big pharmaceutical companies to invest in an endowment to fund this type of center. Fortunately, the US Hereditary Angioedema Association (HAEA), a nonprofit patient advocacy organization, along with four pharmaceutical companies—Shire Human Genetics Therapies Inc., ViroPharma Incorporated (which merged with Shire), Dyax Corp. and CSL Bering—pledged a total of $4.6 million to help make the US HAEA Angioedema Center at UC San Diego Health System a reality. A number of individuals, including those with the disease, also provided private support. … Read the full story from the UC San Diego News Center


Dr. Bruce Zuraw

Dr. Bruce Zuraw

Dr. Bruce Zuraw is director of the US HAEA Angioedema Center at UC San Diego Health System and inaugural recipient of the US HAEA Endowed Chair at UC San Diego. He is professor of medicine and chief of the Division of Rheumatology, Allergy & Immunology.

Dr. Marc Riedl

Dr. Marc Riedl

Marc Riedl, MD, MS, associate professor of medicine, is clinical director of the center.